Abbott receives ce mark for navitor™, the latest-generation transcatheter aortic valve implantation (tavi) system to treat aortic stenosis

Abbott park, ill., may 17, 2021 /prnewswire/ -- abbott (nyse: abt) today announced it has received ce mark for its latest-generation transcatheter aortic valve implantation (tavi) system, navitor™, making the minimally invasive device available for people in europe with severe aortic stenosis who are at high or extreme surgical risk.
ABT Ratings Summary
ABT Quant Ranking